Published in Chem Commun (Camb) on May 18, 2014
Neural systems of reinforcement for drug addiction: from actions to habits to compulsion. Nat Neurosci (2005) 16.18
ChEMBL: a large-scale bioactivity database for drug discovery. Nucleic Acids Res (2011) 14.51
Network pharmacology: the next paradigm in drug discovery. Nat Chem Biol (2008) 8.51
Structure of the human dopamine D3 receptor in complex with a D2/D3 selective antagonist. Science (2010) 5.86
From magic bullets to designed multiple ligands. Drug Discov Today (2004) 4.09
Targeting the endocannabinoid system: to enhance or reduce? Nat Rev Drug Discov (2008) 3.93
The efficiency of multi-target drugs: the network approach might help drug design. Trends Pharmacol Sci (2005) 3.02
Pharmacological profile of the selective FAAH inhibitor KDS-4103 (URB597). CNS Drug Rev (2006) 2.25
Cyclohexylcarbamic acid 3'- or 4'-substituted biphenyl-3-yl esters as fatty acid amide hydrolase inhibitors: synthesis, quantitative structure-activity relationships, and molecular modeling studies. J Med Chem (2004) 2.05
Novel mechanistic class of fatty acid amide hydrolase inhibitors with remarkable selectivity. Biochemistry (2007) 1.90
Molecular determinants of selectivity and efficacy at the dopamine D3 receptor. J Med Chem (2012) 1.87
Multi-target-directed ligands to combat neurodegenerative diseases. J Med Chem (2008) 1.81
Treatment of nicotine addiction: present therapeutic options and pipeline developments. Trends Pharmacol Sci (2011) 1.55
Dopamine D3 receptor antagonists as therapeutic agents. Drug Discov Today (2005) 1.50
Design, synthesis, and structure-activity relationships of alkylcarbamic acid aryl esters, a new class of fatty acid amide hydrolase inhibitors. J Med Chem (2003) 1.50
Polypharmacology - foe or friend? J Med Chem (2013) 1.42
Inhibition of anandamide hydrolysis by cyclohexyl carbamic acid 3'-carbamoyl-3-yl ester (URB597) reverses abuse-related behavioral and neurochemical effects of nicotine in rats. J Pharmacol Exp Ther (2008) 1.29
N-(4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butyl, butenyl and butynyl)arylcarboxamides as novel dopamine D(3) receptor antagonists. Bioorg Med Chem Lett (2003) 1.12
Crystal structure of fatty acid amide hydrolase bound to the carbamate inhibitor URB597: discovery of a deacylating water molecule and insight into enzyme inactivation. J Mol Biol (2010) 1.09
The psychiatric side-effects of rimonabant. Rev Bras Psiquiatr (2009) 1.02
BP 897, a selective dopamine D3 receptor ligand with therapeutic potential for the treatment of cocaine-addiction. CNS Drug Rev (2003) 1.02
N-(omega-(4-(2-methoxyphenyl)piperazin-1-yl)alkyl)carboxamides as dopamine D2 and D3 receptor ligands. J Med Chem (2003) 1.01
Recent advances in the development of dopamine D3 receptor antagonists: a medicinal chemistry perspective. ChemMedChem (2011) 0.99
Synthesis and quantitative structure-activity relationship of fatty acid amide hydrolase inhibitors: modulation at the N-portion of biphenyl-3-yl alkylcarbamates. J Med Chem (2008) 0.97
Occupancy of brain dopamine D3 receptors and drug craving: a translational approach. Neuropsychopharmacology (2012) 0.97
Identification of productive inhibitor binding orientation in fatty acid amide hydrolase (FAAH) by QM/MM mechanistic modelling. Chem Commun (Camb) (2007) 0.95
The role of fragment-based and computational methods in polypharmacology. Drug Discov Today (2011) 0.93
Discovery and molecular basis of potent noncovalent inhibitors of fatty acid amide hydrolase (FAAH). Proc Natl Acad Sci U S A (2011) 0.89
Discovery of a new class of potential multifunctional atypical antipsychotic agents targeting dopamine D3 and serotonin 5-HT1A and 5-HT2A receptors: design, synthesis, and effects on behavior. J Med Chem (2009) 0.87
Molecular alliance-from orthosteric and allosteric ligands to dualsteric/bitopic agonists at G protein coupled receptors. Angew Chem Int Ed Engl (2012) 0.86
Smoking cessation drugs market. Nat Rev Drug Discov (2013) 0.85
Targeting nicotine addiction: the possibility of a therapeutic vaccine. Drug Des Devel Ther (2011) 0.82
Recent advances in the discovery and evaluation of fatty acid amide hydrolase inhibitors. Expert Opin Drug Discov (2010) 0.81
Endogenous cannabinoid and opioid systems and their role in nicotine addiction. Curr Drug Targets (2010) 0.80
Modulation of anxiety through blockade of anandamide hydrolysis. Nat Med (2002) 7.72
Role of endogenous cannabinoids in synaptic signaling. Physiol Rev (2003) 5.70
Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science (2005) 5.12
Oleylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR-alpha. Nature (2003) 4.60
An endocannabinoid mechanism for stress-induced analgesia. Nature (2005) 4.03
Automated design of ligands to polypharmacological profiles. Nature (2012) 3.54
The nuclear receptor peroxisome proliferator-activated receptor-alpha mediates the anti-inflammatory actions of palmitoylethanolamide. Mol Pharmacol (2004) 3.38
Characterization of the fatty acid amide hydrolase inhibitor cyclohexyl carbamic acid 3'-carbamoyl-biphenyl-3-yl ester (URB597): effects on anandamide and oleoylethanolamide deactivation. J Pharmacol Exp Ther (2004) 3.14
Molecular composition of the endocannabinoid system at glutamatergic synapses. J Neurosci (2006) 2.81
Anandamide suppresses pain initiation through a peripheral endocannabinoid mechanism. Nat Neurosci (2010) 2.73
A peripheral mechanism for CB1 cannabinoid receptor-dependent modulation of feeding. J Neurosci (2002) 2.52
CASD-NMR: critical assessment of automated structure determination by NMR. Nat Methods (2009) 2.50
Flow cytometric analysis of inflammatory cells in ischemic rat brain. Stroke (2002) 2.50
Rapid broad-spectrum analgesia through activation of peroxisome proliferator-activated receptor-alpha. J Pharmacol Exp Ther (2006) 2.30
Structure of an intermediate state in protein folding and aggregation. Science (2012) 2.24
RNA interference suggests a primary role for monoacylglycerol lipase in the degradation of the endocannabinoid 2-arachidonoylglycerol. Mol Pharmacol (2004) 2.12
Cyclohexylcarbamic acid 3'- or 4'-substituted biphenyl-3-yl esters as fatty acid amide hydrolase inhibitors: synthesis, quantitative structure-activity relationships, and molecular modeling studies. J Med Chem (2004) 2.05
URB602 inhibits monoacylglycerol lipase and selectively blocks 2-arachidonoylglycerol degradation in intact brain slices. Chem Biol (2007) 2.05
A role for monoglyceride lipase in 2-arachidonoylglycerol inactivation. Chem Phys Lipids (2002) 1.98
The fatty acid amide hydrolase inhibitor URB597 (cyclohexylcarbamic acid 3'-carbamoylbiphenyl-3-yl ester) reduces neuropathic pain after oral administration in mice. J Pharmacol Exp Ther (2007) 1.96
Crystal structures of anaplastic lymphoma kinase in complex with ATP competitive inhibitors. Biochemistry (2010) 1.94
Selective inhibition of 2-AG hydrolysis enhances endocannabinoid signaling in hippocampus. Nat Neurosci (2005) 1.92
PER2 controls lipid metabolism by direct regulation of PPARγ. Cell Metab (2010) 1.91
Actions of the FAAH inhibitor URB597 in neuropathic and inflammatory chronic pain models. Br J Pharmacol (2006) 1.83
Long-term plasticity of endocannabinoid signaling induced by developmental febrile seizures. Neuron (2003) 1.80
Prediction of aggregation rate and aggregation-prone segments in polypeptide sequences. Protein Sci (2005) 1.80
Antidepressant-like activity of the fatty acid amide hydrolase inhibitor URB597 in a rat model of chronic mild stress. Biol Psychiatry (2007) 1.79
Fast and accurate predictions of protein NMR chemical shifts from interatomic distances. J Am Chem Soc (2009) 1.75
Oleoylethanolamide stimulates lipolysis by activating the nuclear receptor peroxisome proliferator-activated receptor alpha (PPAR-alpha). J Biol Chem (2004) 1.73
Food intake regulates oleoylethanolamide formation and degradation in the proximal small intestine. J Biol Chem (2006) 1.71
The search for the palmitoylethanolamide receptor. Life Sci (2005) 1.68
Stimulation of endocannabinoid formation in brain slice cultures through activation of group I metabotropic glutamate receptors. Mol Pharmacol (2005) 1.66
Selective N-acylethanolamine-hydrolyzing acid amidase inhibition reveals a key role for endogenous palmitoylethanolamide in inflammation. Proc Natl Acad Sci U S A (2009) 1.64
A key role for diacylglycerol lipase-alpha in metabotropic glutamate receptor-dependent endocannabinoid mobilization. Mol Pharmacol (2007) 1.63
Safety of non-antiarrhythmic drugs that prolong the QT interval or induce torsade de pointes: an overview. Drug Saf (2002) 1.62
Cerebrospinal anandamide levels are elevated in acute schizophrenia and are inversely correlated with psychotic symptoms. Neuropsychopharmacology (2004) 1.55
Fatty acid amide hydrolase inhibition heightens anandamide signaling without producing reinforcing effects in primates. Biol Psychiatry (2008) 1.54
The endogenous cannabinoid anandamide produces delta-9-tetrahydrocannabinol-like discriminative and neurochemical effects that are enhanced by inhibition of fatty acid amide hydrolase but not by inhibition of anandamide transport. J Pharmacol Exp Ther (2007) 1.53
The role of aromaticity, exposed surface, and dipole moment in determining protein aggregation rates. Protein Sci (2004) 1.50
Design, synthesis, and structure-activity relationships of alkylcarbamic acid aryl esters, a new class of fatty acid amide hydrolase inhibitors. J Med Chem (2003) 1.50
A catalytically silent FAAH-1 variant drives anandamide transport in neurons. Nat Neurosci (2011) 1.50
Oleoylethanolamide, an endogenous PPAR-alpha agonist, lowers body weight and hyperlipidemia in obese rats. Neuropharmacology (2005) 1.49
Inhibition of the renin-angiotensin system in chronic kidney disease: a critical look to single and dual blockade. Nephron Clin Pract (2009) 1.46
A coupled equilibrium shift mechanism in calmodulin-mediated signal transduction. Structure (2008) 1.45
QT prolongation through hERG K(+) channel blockade: current knowledge and strategies for the early prediction during drug development. Med Res Rev (2005) 1.42
Diaryl Urea: A Privileged Structure in Anticancer Agents. Curr Med Chem (2016) 1.40
Using NMR chemical shifts as structural restraints in molecular dynamics simulations of proteins. Structure (2010) 1.36
Synthesis and characterization of a peripherally restricted CB1 cannabinoid antagonist, URB447, that reduces feeding and body-weight gain in mice. Bioorg Med Chem Lett (2008) 1.36
The endogenous cannabinoid anandamide has effects on motivation and anxiety that are revealed by fatty acid amide hydrolase (FAAH) inhibition. Neuropharmacology (2007) 1.35
Protein conformational transitions: the closure mechanism of a kinase explored by atomistic simulations. J Am Chem Soc (2009) 1.32
Calpain-1 regulates Bax and subsequent Smac-dependent caspase-3 activation in neutrophil apoptosis. J Biol Chem (2003) 1.31
Pharmacological characterization of hydrolysis-resistant analogs of oleoylethanolamide with potent anorexiant properties. J Pharmacol Exp Ther (2006) 1.31
Modulation of meal pattern in the rat by the anorexic lipid mediator oleoylethanolamide. Neuropsychopharmacology (2003) 1.30
Endocannabinoid signal in the gut controls dietary fat intake. Proc Natl Acad Sci U S A (2011) 1.29
Inhibition of anandamide hydrolysis by cyclohexyl carbamic acid 3'-carbamoyl-3-yl ester (URB597) reverses abuse-related behavioral and neurochemical effects of nicotine in rats. J Pharmacol Exp Ther (2008) 1.29
Anxiolytic-like properties of the anandamide transport inhibitor AM404. Neuropsychopharmacology (2006) 1.28
Fat-induced satiety factor oleoylethanolamide enhances memory consolidation. Proc Natl Acad Sci U S A (2009) 1.25
Deficiency of lipoprotein lipase in neurons modifies the regulation of energy balance and leads to obesity. Cell Metab (2011) 1.25
Uncoupling of the endocannabinoid signalling complex in a mouse model of fragile X syndrome. Nat Commun (2012) 1.24
Lipidomic analysis of endocannabinoid metabolism in biological samples. J Chromatogr B Analyt Technol Biomed Life Sci (2009) 1.23
Blind testing of routine, fully automated determination of protein structures from NMR data. Structure (2012) 1.23
Synergistic antinociception by the cannabinoid receptor agonist anandamide and the PPAR-alpha receptor agonist GW7647. Eur J Pharmacol (2007) 1.22
Characterization of the conformational equilibrium between the two major substates of RNase A using NMR chemical shifts. J Am Chem Soc (2012) 1.20
The endocannabinoid system as a target for novel anxiolytic and antidepressant drugs. Int Rev Neurobiol (2009) 1.20
Identification of biosynthetic precursors for the endocannabinoid anandamide in the rat brain. J Lipid Res (2007) 1.20
Structural basis for CARM1 inhibition by indole and pyrazole inhibitors. Biochem J (2011) 1.20
Single-molecule pulling simulations can discern active from inactive enzyme inhibitors. J Am Chem Soc (2010) 1.19
Acute intracerebroventricular administration of palmitoylethanolamide, an endogenous peroxisome proliferator-activated receptor-alpha agonist, modulates carrageenan-induced paw edema in mice. J Pharmacol Exp Ther (2007) 1.18
Blockade of nicotine reward and reinstatement by activation of alpha-type peroxisome proliferator-activated receptors. Biol Psychiatry (2011) 1.18
Recipes for the selection of experimental protein conformations for virtual screening. J Chem Inf Model (2010) 1.17
Targeted enhancement of oleoylethanolamide production in proximal small intestine induces across-meal satiety in rats. Am J Physiol Regul Integr Comp Physiol (2008) 1.16
Effects of levodopa on endocannabinoid levels in rat basal ganglia: implications for the treatment of levodopa-induced dyskinesias. Eur J Neurosci (2003) 1.16
Deficient liver biosynthesis of docosahexaenoic acid correlates with cognitive impairment in Alzheimer's disease. PLoS One (2010) 1.15
Central administration of palmitoylethanolamide reduces hyperalgesia in mice via inhibition of NF-kappaB nuclear signalling in dorsal root ganglia. Eur J Pharmacol (2009) 1.14
Analysis of the distributed computing approach applied to the folding of a small beta peptide. Proc Natl Acad Sci U S A (2003) 1.13
Molecular basis of cyclooxygenase enzymes (COXs) selective inhibition. Proc Natl Acad Sci U S A (2010) 1.12
Effects of palmitoylethanolamide on signaling pathways implicated in the development of spinal cord injury. J Pharmacol Exp Ther (2008) 1.12
N-Acylethanolamines in human reproductive fluids. Chem Phys Lipids (2002) 1.11
Anandamide hydrolysis: a new target for anti-anxiety drugs? Trends Mol Med (2003) 1.11
Consistent improvement of cross-docking results using binding site ensembles generated with elastic network normal modes. J Chem Inf Model (2009) 1.11
A second generation of carbamate-based fatty acid amide hydrolase inhibitors with improved activity in vivo. ChemMedChem (2009) 1.11
Insight into the kinetic of amyloid beta (1-42) peptide self-aggregation: elucidation of inhibitors' mechanism of action. Chembiochem (2007) 1.10
Peroxisome proliferator-activated receptor α mediates acute effects of palmitoylethanolamide on sensory neurons. J Neurosci (2012) 1.10
Peripheral antinociceptive effects of inhibitors of monoacylglycerol lipase in a rat model of inflammatory pain. Br J Pharmacol (2011) 1.10
Anandamide levels in cerebrospinal fluid of first-episode schizophrenic patients: impact of cannabis use. Schizophr Res (2007) 1.09
Postprandial increase of oleoylethanolamide mobilization in small intestine of the Burmese python (Python molurus). Am J Physiol Regul Integr Comp Physiol (2005) 1.09
2-arachidonoylglycerol signaling in forebrain regulates systemic energy metabolism. Cell Metab (2012) 1.09
The effect of cannabidiol and URB597 on conditioned gaping (a model of nausea) elicited by a lithium-paired context in the rat. Psychopharmacology (Berl) (2007) 1.08
The thrifty lipids: endocannabinoids and the neural control of energy conservation. Trends Neurosci (2012) 1.08
The endocannabinoid system as a target for the treatment of cannabis dependence. Neuropharmacology (2008) 1.07
Proinflammatory stimuli control N-acylphosphatidylethanolamine-specific phospholipase D expression in macrophages. Mol Pharmacol (2011) 1.07
Accurate random coil chemical shifts from an analysis of loop regions in native states of proteins. J Am Chem Soc (2009) 1.07
Targeted lipidomics: signaling lipids and drugs of abuse. Prostaglandins Other Lipid Mediat (2005) 1.07
Anandamide elevation in cerebrospinal fluid in initial prodromal states of psychosis. Br J Psychiatry (2009) 1.06
Peripheral FAAH inhibition causes profound antinociception and protects against indomethacin-induced gastric lesions. Pharmacol Res (2012) 1.06
Endocannabinoid transport tightly controls 2-arachidonoyl glycerol actions in the hippocampus: effects of low temperature and the transport inhibitor AM404. Eur J Neurosci (2004) 1.06